Zheng Di, Xia Kezhou, Yu Ling, Gong Changtian, Shi Yubo, Li Wei, Qiu Yonglong, Yang Jian, Guo Weichun
Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, China.
Front Cell Dev Biol. 2021 Jul 23;9:699212. doi: 10.3389/fcell.2021.699212. eCollection 2021.
Osteosarcoma is the most common malignant bone tumor, and although there has been significant progress in its management, metastases often herald incurable disease. Here we defined genes differentially expressed between primary and metastatic osteosarcoma as metastasis-related genes (MRGs) and used them to construct a novel six-MRG prognostic signature for overall survival of patients with osteosarcoma. Validation in internal and external datasets confirmed satisfactory accuracy and generalizability of the prognostic model, and a nomogram based on the signature and clinical variables was constructed to aid clinical decision-making. Of the six MRGs, is a well-documented tumor suppressor gene that is poorly defined in osteosarcoma. Consistent with tumor suppressor function, FHIT was downregulated in osteosarcoma cells and human osteosarcoma samples. FHIT overexpression inhibited osteosarcoma proliferation, migration, and invasion both and . Mechanistically, FHIT overexpression upregulate the epithelial marker E-cadherin while repressing the mesenchymal markers N-cadherin and vimentin. Our six-MRG signature represents a novel and clinically useful prognostic biomarker for patients with osteosarcoma, and FHIT might represent a therapeutic target by reversing epithelial to mesenchymal transition.
骨肉瘤是最常见的恶性骨肿瘤,尽管其治疗已取得显著进展,但转移往往预示着疾病无法治愈。在此,我们将原发性和转移性骨肉瘤之间差异表达的基因定义为转移相关基因(MRG),并利用这些基因构建了一种用于骨肉瘤患者总生存的新型六基因MRG预后特征。在内部和外部数据集上的验证证实了该预后模型具有令人满意的准确性和通用性,并构建了基于该特征和临床变量的列线图以辅助临床决策。在这六个MRG中, 是一个有充分文献记载的肿瘤抑制基因,在骨肉瘤中尚未得到充分研究。与肿瘤抑制功能一致,FHIT在骨肉瘤细胞和人骨肉瘤样本中表达下调。FHIT过表达在 和 中均抑制骨肉瘤的增殖、迁移和侵袭。从机制上讲,FHIT过表达上调上皮标志物E-钙黏蛋白,同时抑制间充质标志物N-钙黏蛋白和波形蛋白。我们的六基因MRG特征代表了一种用于骨肉瘤患者的新型且临床有用的预后生物标志物,并且FHIT可能通过逆转上皮-间充质转化而成为一个治疗靶点。